Oncology Account Executive

Innovations in liquid biopsy technology demonstrate a more accurate method to infer in-tissue copy number from ctDNA, detection of a novel non-tumor derived pseudogene of GNA11, and development of an epigenetic-based method for precise tumor burden measurementMENLO PARK, Calif., April 25, 2025 /PRNewswire/ -- BillionToOne , a molecular diagnostics company with a mission to create powerful and accurate tests accessible to all, announced today several abstract presentations that will be showcased at the American Association of Cancer Research (AACR) Annual Meeting on April 25–30, 2025, in Chicago, IL.Each abstract highlights BillionToOne's relentless focus in advancing the field of liquid biopsy technology:Title: "Tumor fraction estimation and tissue copy number inference using copy number signal from a liquid biopsy assay"Session Time: 4/29/25 at 9:00 AM - 12:00 PMLocation: Poster Section 20Title: "Detection of a novel GNA11 processed pseudogene from cfDNA and implications for liquid biopsy"Session Time: 4/29/25 at 2:00 - 5:00 PMLocation: Poster Section 31Title: "Circulating cell-free methylated tumor DNA measurements correlate with plasma VAF-based tumor fraction estimates"Session Time: 4/29/25 at 2:00 - 5:00 PMLocation: Poster Section 32"These data presented at AACR represent our dedication in advancing liquid biopsy testing with our proprietary single molecule precision technology and setting new standards in what can be achieved with plasma-based tests," said Dr. Gary Palmer, Chief Medical Officer, Oncology at BillionToOne. "Together, these innovations enhance the accuracy and robustness of ctDNA-based cancer profiling and monitoring, which will ultimately enable more precise treatment decisions for patients."About BillionToOneHeadquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's single-molecule NGS (smNGS) platform, which includes the patented Quantitative Counting Template (QCT) technology, is the only multiplex methodology that can accurately count DNA molecules at the single-molecule level. For more information, please visit www.billiontoone.com .Media Contact: [email protected]SOURCE BillionToOne

BillionToOne to present new data at AACR Annual Meeting 2025.

UNITY is the only commercially available non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a single maternal blood draw.MENLO PARK, Calif., March 18, 2025 /PRNewswire/ -- BillionToOne, Inc. , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, has reached a significant milestone of conducting one million UNITY prenatal tests. This achievement highlights the company's exceptional execution and superior product differentiation, which has fueled remarkable year-over-year growth and established BillionToOne as a leading player in the U.S. prenatal testing market.Powered by BillionToOne's patented Quantitative Counting Template™ (QCT™) molecular counting technology, the UNITY Fetal Risk Screen™ stands apart as the only prenatal genetic test that directly assesses a baby's risk for recessively inherited conditions, including cystic fibrosis, spinal muscular atrophy (SMA), and sickle cell disease, without requiring a male partner's sample or invasive testing."Surpassing 1 million UNITY tests in only 5 years is not just a milestone for our company, but a testament to how our technology is transforming prenatal care," said Oguzhan Atay, Ph.D., Co-Founder and CEO of BillionToOne. "What is more impressive is that our annual run-rate is already above 500,000 UNITY tests this year, indicating truly exponential growth and establishment of UNITY as the next standard in prenatal care. This achievement would not be possible without the dedication of our employees, the support of our partners, and the trust of our healthcare providers."BillionToOne has firmly established itself as the fastest-growing molecular diagnostics laboratory, with 100% year-over-year revenue growth in 2024.This milestone further solidifies BillionToOne's position as a leading provider in democratizing access to essential prenatal testing, particularly for those who need it most